As filed with the Securities
and Exchange Commission on July 29, 2024
Registration No. 333-
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
S-3
REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933
ANAVEX
LIFE SCIENCES CORP.
(Exact Name of Registrant as
Specified in Its Charter)
| Nevada |
|
|
98-0608404
|
| (State
or Other Jurisdiction of Incorporation or Organization) |
|
|
(I.R.S.
Employer Identification Number) |
630 5th Avenue, 20th Floor
New York, NY USA 10111
Telephone: (844) 689-3939
(Address, Including Zip Code,
and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
Christopher U. Missling,
PhD
Chief Executive Officer
630 5th Avenue, 20th Floor
New York, NY USA 10111
Telephone: (844) 689-3939
(Name, Address, Including Zip
Code, and Telephone Number, Including Area Code, of Agent for Service)
Copy to:
Clayton Parker, Esq.
K&L Gates LLP
200 S. Biscayne Blvd., Ste.
3900
Miami, Florida 33131
Telephone: (305) 539-3306
Approximate date of commencement
of proposed sale to public: From time to time after this Registration Statement becomes effective.
If the only securities being
registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐
If any of the securities being
registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other
than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒
If this Form is filed to register
additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective
amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. ☐
If this Form is a registration
statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the
Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐
If this Form is a post-effective
amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional
classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging
growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting
company” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one):
| Large
accelerated filer |
|
|
☒ |
|
|
Accelerated
filer |
|
|
☐ |
| Non-accelerated
filer |
|
|
☐ |
|
|
Smaller
reporting company |
|
|
☒ |
| |
|
|
|
|
|
Emerging
growth company |
|
|
☐ |
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
The registrant hereby amends
this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further
amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a)
of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange
Commission, acting pursuant to said Section 8(a), may determine.
The information in this prospectus
is not complete and subject to change. We may not sell these securities until the registration statement filed with the Securities and
Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these
securities in any state where the offer or sale is not permitted.
SUBJECT TO COMPLETION, DATED
JULY 29, 2024
PROSPECTUS
ANAVEX LIFE SCIENCES CORP.
$150,000,000
of
Common Stock
Anavex Life Sciences Corp.,
a Nevada corporation (“us”, “we”, “our”, “Anavex” or the
“Company”) may offer and sell from time to time, in one or more series or issuances and on terms that we will determine
at the time of the offering, shares of our common stock, par value $0.001 per share described in this prospectus, up to an aggregate
amount of $150,000,000.
This prospectus describes
some of the general terms that may apply to an offering of our common stock. Each time we sell common stock pursuant to this prospectus,
we will file a prospectus supplement to this prospectus that contains specific information about the offering. Such supplements may also
add, update or change information contained in this prospectus. You should carefully read this prospectus and the applicable prospectus
supplement before you invest in our common stock. This prospectus may not be used to consummate sales of common stock unless accompanied
by a prospectus supplement.
Common stock may be sold directly
by us, through dealers or agents designated from time to time, to or through underwriters or through a combination of these methods.
See “Plan of Distribution” in this prospectus. We may also describe the plan of distribution for any particular offering
of the common stock in any applicable prospectus supplement. If any agents, underwriters or dealers are involved in the sale of any common
stock in respect of which this prospectus is being delivered, we will disclose their names and the nature of our arrangements with them
in a prospectus supplement. The net proceeds we expect to receive from any such sale will also be included in the sales agreement prospectus
as well as a prospectus supplement to this base prospectus.
Our common stock is currently
quoted on The Nasdaq Capital Market under the symbol “AVXL”. On July 22, 2024, the last reported sale price of our common
stock was $5.91 per share.
Investing in our securities
involves a high degree of risk. See the section entitled “Risk Factors” on page 11 of this prospectus and in the documents
we filed with the Securities and Exchange Commission that are incorporated in this prospectus by reference for certain risks and uncertainties
you should consider.
Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy
or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
This prospectus is dated , 2024.
TABLE OF CONTENTS
No dealer, salesperson
or other person has been authorized to give any information or to make any representations other than those contained or incorporated
by reference in this prospectus or any accompanying prospectus supplement in connection with the offer made by this prospectus or any
accompanying prospectus supplement and, if given or made, such information or representations must not be relied upon as having been
authorized by Anavex Life Sciences Corp. or any such person. Neither the delivery of this prospectus or any accompanying prospectus supplement
nor any sale made hereunder and thereunder shall under any circumstances create an implication that there has been no change in the affairs
of Anavex Life Sciences Corp. since the date hereof. This prospectus or any accompanying prospectus supplement does not constitute an
offer or solicitation by anyone in any state in which such offer or solicitation is not authorized or in which the person making such
offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation.
ABOUT THIS PROSPECTUS
This prospectus of Anavex
Life Sciences Corp., a Nevada corporation (collectively with all of its subsidiaries, the “Company”, “Anavex”,
or “we”, “us”, or “our”) is a part of a registration statement on Form S-3 that
we filed with the Securities and Exchange Commission (“SEC”) utilizing a “shelf” registration process.
Under this shelf registration process, we may, from time to time, sell shares of common stock in one or more offerings up to a total
dollar amount of $150,000,000 as described in this prospectus.
The registration statement
of which this prospectus is a part provides additional information about us and the securities offered under this prospectus. The registration
statement, including the exhibits and the documents incorporated herein by reference, can be read on the SEC website or at the SEC offices
mentioned under the heading “Prospectus Summary - Where You Can Find More Information.”
We will provide a prospectus
supplement containing specific information about the amounts, prices and terms of the securities for a particular offering. The prospectus
supplement may add, update or change information in this prospectus. If the information in the prospectus is inconsistent with a prospectus
supplement, you should rely on the information in that prospectus supplement. You should read both this prospectus and, if applicable,
any prospectus supplement. See “Prospectus Summary — Where You Can Find More Information” for more information.
You should rely only on the
information contained or incorporated by reference in this prospectus and in any prospectus supplement. We have not authorized any other
person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely
on it. We are not making offers to sell or solicitations to buy the securities in any jurisdiction in which an offer or solicitation
is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful
to make an offer or solicitation. You should not assume that the information in this prospectus or any prospectus supplement, as well
as the information we file or previously filed with the SEC that we incorporate by reference in this prospectus or any prospectus supplement,
is accurate as of any date other than the date of such document. Our business, financial condition, results of operations and prospects
may have changed since those dates.
PROSPECTUS SUMMARY
The items in the following
summary are described in more detail later in this prospectus. This summary does not contain all of the information you should consider.
Before investing in our securities, you should read the entire prospectus carefully, including the “Risk Factors” beginning
on page 10 and the financial statements incorporated by reference.
Our Business
Anavex Life Sciences Corp.
is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine
to central nervous system (“CNS”) diseases with high unmet need. We analyze genomic data from clinical trials to identify
biomarkers, which we use in the analysis of our clinical trials.
Our lead product candidate,
ANAVEX®2-73 (blarcamesine), is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially
other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder
caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (“MECP2”).
We currently have two core
programs and two seed programs. Our core programs are at various stages of clinical and preclinical development, in neurodegenerative
and neurodevelopmental diseases.
Clinical Trials Overview
Alzheimer’s Disease
In November 2016, we completed
a Phase 2a clinical trial, consisting of Part A and Part B, which lasted a total of 57 weeks, for ANAVEX®2-73 in mild-to-moderate
Alzheimer’s patients. This open-label randomized trial in Australia met both primary and secondary endpoints and was designed to
assess the safety and exploratory efficacy of ANAVEX®2-73 in 32 patients. ANAVEX®2-73 targets sigma-1 and
muscarinic receptors, which have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular
homeostasis and to reverse the pathological hallmarks observed in Alzheimer’s disease. In October 2017, we presented positive pharmacokinetic
(“PK”) and pharmacodynamic (“PD”) data from the Phase 2a clinical trial, which established a concentration-effect
relationship between ANAVEX®2-73 and trial measurements. These measures obtained from all patients who participated in
the entire 57 weeks include exploratory cognitive and functional scores as well as biomarker signals of brain activity. Additionally,
the clinical trial appeared to show that ANAVEX®2-73 activity was enhanced by its active metabolite (ANAVEX19-144), which
also targets the SIGMAR1 receptor and has a half-life approximately twice as long as the parent molecule.
Two consecutive trial extensions
for the Phase 2a trial have allowed participants who completed the 52-week Part B of the trial to continue taking ANAVEX®2-73,
providing an opportunity to gather extended safety data for a cumulative time period of five years. In August 2020, patients completing
these Phase 2a trial extensions were granted continued access to treatment with ANAVEX®2-73 through the Australian Government
Department of Health - Therapeutic Goods Administration’s compassionate use Special Access Scheme.
A larger Phase 2b/3 double-blind,
placebo-controlled trial of ANAVEX®2-73 in Alzheimer’s disease commenced in August 2018. The Phase 2b/3 trial enrolled
509 patients, which were treated with a convenient once-daily oral formulation of ANAVEX®2-73 for 48 weeks, randomized
1:1:1 to two different ANAVEX®2-73 doses or placebo. The trial took place at 52 sites across North America, Europe and
Australia. Primary and secondary endpoints to assess safety and both cognitive and functional efficacy, were measured through the Alzheimer’s
Disease Assessment Scale - Cognitive Subscale test (“ADAS-Cog”), Alzheimer’s Disease Cooperative Study - Activities
of Daily Living (“ADCS-ADL”) and Clinical Dementia Rating - Sum of Boxes for cognition and function (“CDR-SB”).
In addition to the primary endpoints, the ANAVEX®2-73 Phase 2b/3 trial design incorporated pre-specified statistical analyses
related to potential genomic precision medicine biomarkers previously identified in the ANAVEX®2-73 Phase 2a clinical
trial. The trial was completed in mid-2022 and, in December 2022, the Company presented positive topline results from the Phase 2b/3
clinical trial.
Blarcamesine
significantly slowed clinical progression by 38.5% and 34.6% at 48 weeks
in 50 mg and 30 mg groups vs. placebo, respectively, on the prespecified primary cognitive endpoint ADAS-Cog13. The protocol was
designed with ADAS-Cog13 and ADCS-ADL as co-primary endpoints. The functional co-primary endpoint, ADCS-ADL, was trending positive but
did not reach significance at Week 48. The prespecified key secondary composite endpoint CDR-SB, was significant at both 30 mg and 50
mg at Week 48. The findings are supported by biomarkers, including plasma Aβ42/40-ratio and reduction of brain atrophy. Blarcamesine
significantly slowed brain atrophy in key regions of interest, including the whole brain by 37.6%, total grey matter by 63.5%, and lateral
ventricles by 25.1%.
For the
primary endpoint ADAS-Cog13, blarcamesine is significantly better than placebo for both 50 mg (−2.149; P = 0.021) at 48 weeks and
for 30 mg blarcamesine dosage groups (−1.934; P = 0.026) at 48 weeks. The key secondary endpoint CDR-SB was significantly improved
vs. placebo in both 50 mg (−0.465; P = 0.045) and 30 mg (−0.502; P = 0.020) assigned dose groups. CGI-I was significantly
improved in both 50 mg (−0.314; P = 0.008) and 30 mg (−0.248; P = 0.024) groups.
In the respective safety population,
common treatment-emergent adverse events included dizziness, which was transient and mostly mild to moderate in severity, and occurred
in 120 participants (35.8%) during titration and in 76 participants (25.2%) during maintenance with ANAVEX®2-73 and 10 (6.0%) during
titration and 9 (5.6%) during maintenance with placebo.
A subsequent long-term open
label extension study of ANAVEX®2-73, entitled the ATTENTION-AD trial was initiated for patients who completed the 48-week
Phase 2b/3 placebo-controlled trial referenced above. This trial extension for a duration of up to 96 additional weeks was completed
in June 2024. The trial will provide longer term safety and efficacy of ANAVEX®2-73 in persons with Alzheimer’s
disease.
Rett Syndrome
In February 2016, we presented
positive preclinical data for ANAVEX®2-73 in Rett syndrome, a rare neurodevelopmental disease. The data demonstrated dose
related and significant improvements in an array of behavioral and gait paradigms in a mouse model with an MECP2-null mutation that causes
neurological symptoms that mimic Rett syndrome. The study was funded by the International Rett Syndrome Foundation (“Rettsyndrome.org”).
In January 2017, we were awarded a financial grant from Rettsyndrome.org of a minimum of $0.6 million to cover some of the costs of a
multicenter Phase 2 clinical trial of ANAVEX®2-73 for the treatment of Rett syndrome. This award was received in quarterly
instalments which commenced during fiscal 2018.
In March 2019, we commenced
the first Phase 2 clinical trial in a planned Rett syndrome program of ANAVEX®2-73 for the treatment of Rett syndrome.
The clinical trials are being conducted in a range of patient age demographics and geographic regions, utilizing an oral liquid once-daily
formulation of ANAVEX®2-73.
The first Phase 2 trial, (ANAVEX®2-73-RS-001),
which took place in the United States, was completed in December 2020. This trial was a randomized double-blind, placebo-controlled safety,
tolerability, PK and efficacy trial of oral liquid ANAVEX®2-73 formulation in 25 adult female patients with Rett syndrome
over a 7-week treatment period including ANAVEX®2-73-specific genomic precision medicine biomarkers. The primary endpoint
of the trial was safety. The dosing of 5 mg ANAVEX®2-73 was well-tolerated and demonstrated dose-proportional PK. All
secondary efficacy endpoints of the trial showed statistically significant and clinically meaningful response in the Rett Syndrome Behaviour
Questionnaire (“RSBQ”) response, when compared to placebo, in the intent to treat (“ITT”) cohort
(all participants, p = 0.011). 66.7% of ANAVEX®2-73 treated subjects showed a statistically significant improvement in
RSBQ response as compared to 10% of the subjects on placebo in the ITT cohort (all participants, p = 0.011). ANAVEX®2-73
treatment resulted in a sustained improvement in Clinical Global Impression Improvement (CGI-I) response throughout the 7-week clinical
trial, when compared to placebo in the ITT cohort (all participants, p = 0.014). Consistent with previous ANAVEX®2-73
clinical trials, patients carrying the common form of the SIGMAR1 gene treated with ANAVEX®2-73 experienced stronger improvements
in the prespecified efficacy endpoints.
The second, international
trial of ANAVEX®2-73 for the treatment of Rett syndrome, called the AVATAR trial, commenced in June 2019. This trial took
place in Australia and the United Kingdom using a higher dose than the U.S. based Phase 2 trial for Rett syndrome. The trial was a Phase
3 randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of ANAVEX®2-73 in 33 adult patients
over a 7-week treatment period including ANAVEX®2-73 specific precision medicine biomarkers. Based upon the input from
the successful U.S. Phase 2 Rett syndrome trial (ANAVEX®2-73-RS-001), we updated the endpoints for the AVATAR trial (ANAVEX®2-73-RS-002)
to appropriately assess the clinically meaningful outcome following International Conference on Harmonization (ICH) guidelines. These
updates were approved by the respective regulatory authorities in the U.K. and in Australia, respectively, where the AVATAR trial was
conducted.
The data from the AVATAR trial
was released in February 2022. The clinical trial met all primary and secondary efficacy and safety endpoints, with consistent improvements
in primary efficacy endpoint, RSBQ response (p = 0.037), and secondary efficacy endpoints, Anxiety, Depression, and Mood Scale (ADAMS)
(p = 0.010) and CGI-I (p = 0.037) response. Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions
in Rett syndrome symptoms. Convenient once daily oral liquid doses of up to 30 mg of ANAVEX®2-73 were also well tolerated
with good medication compliance. All patients who participated in the trial were eligible to receive ANAVEX®2-73 under
a voluntary open label extension protocol and subsequent Compassionate Use Program.
The very first trial of ANAVEX®2-73
in pediatric Rett syndrome patients, the EXCELLENCE trial, completed enrollment in February 2023. This randomized, double-blind, placebo-controlled
Phase 2/3 trial in pediatric patients with Rett syndrome included trial sites in Canada, Australia, and the United Kingdom. 92 pediatric
patients with Rett syndrome between the ages of 5 through 17 years were treated daily with up to 30 mg ANAVEX®2-73. Participants
were randomized 2:1 (ANAVEX®2-73:placebo) for 12 weeks, followed by a week 16 safety visit and topline results from this
trial were announced in early January 2024.
After 12 weeks, the study
showed improvement on the key co-primary endpoint RSBQ, which is a detailed 45-item questionnaire for assessing multiple Rett syndrome
characteristics by the patients’ caregivers. The other co-primary endpoint, the CGI-I, which represents a less granular assessment
by the site investigators using a seven-point scoring (one=“very much improved” to seven=“very much worse”),
was not met.
In an ad-hoc analysis, using
the predefined mixed-effect model for repeated measure (MMRM) method, after 12 weeks of treatment, ANAVEX®2-73-treated
patients improved LS Mean (SE) -12.93 (2.150) points on their RSBQ total score compared to LS Mean (SE) -8.32 (2.537) points in placebo-treated
patients. The LS Mean difference (SE) of -4.61 (2.439) points between treated and placebo groups did not reach statistical significance
(n=77; p=0.063). ANAVEX®2-73-treated patients demonstrated a rapid onset of action with improvements at 4 weeks after
treatment with a RSBQ total score LS Mean (SE) -10.32 (2.086) points in the drug-treated group compared to a LS Mean (SE) -5.67 (2.413)
points in placebo-treated patients. The LS Mean difference of -4.65 (2.233) points between treated and placebo groups was statistically
significant (n=77; p=0.041).
The key secondary endpoint,
the ADAMS, trended favorably. In the same analysis, scores for all RSBQ and ADAMS subscales improved over the course of the study. Collectively,
the RSBQ and ADAMS demonstrated improvements in multiple areas, impacting positively in particular repetitive movements, nighttime disruptive
behaviors, and social avoidance.
A preliminary review of the
safety results indicates there were no new safety signals in the EXCELLENCE study, reinforcing the favorable and manageable safety profile
observed with ANAVEX®2-73 to date.
All patients who participated
in the trial were eligible to receive ANAVEX®2-73 under a voluntary open label extension protocol.
A high enrollment rate in
the OLE of over 91% and the high level of requests for the Compassionate Use Program (93%) provide solid numerical evidence for the reported
positive Real World Evidence (RWE) from patients with Rett syndrome under Compassionate Use Authorization. Families whose children were
previously on drug or placebo in the placebo-controlled trial commented favorably on the improvement of their child’s daily life
due to ANAVEX®2-73 treatment in the Compassionate Use Program.
Parkinson’s Disease
In September 2016, we presented
positive preclinical data for ANAVEX®2-73 in an animal model of Parkinson’s disease, which demonstrated significant
improvements on behavioral, histopathological, and neuroinflammatory endpoints. The study was funded by the Michael J. Fox Foundation.
Additional data announced in October 2017 indicated that ANAVEX®2-73 induced robust neurorestoration in experimental Parkinsonism.
We believe the encouraging results we have gathered in this preclinical model, coupled with the favorable profile of this product candidate
in the Alzheimer’s disease trial, support the notion that ANAVEX®2-73 has the potential to treat Parkinson’s
disease dementia.
In October 2020, we completed
a double-blind, randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX®2-73 in Parkinson’s disease
dementia in Spain and Australia, to study the effect of the compound on both the cognitive and motor impairment of Parkinson’s
disease. The Phase 2 trial enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX®2-73
doses, 30 mg and 50 mg, or placebo. The ANAVEX®2-73 Phase 2 Parkinson’s disease dementia trial design incorporated
genomic precision medicine biomarkers identified in the ANAVEX®2-73 Phase 2a Alzheimer’s disease trial.
The trial demonstrated that
ANAVEX®2-73 was safe and well tolerated in oral doses up to 50 mg once daily. The results showed clinically meaningful,
dose-dependent, and statistically significant improvements in the Cognitive Drug Research (“CDR”) computerized assessment
system analysis. Treatment with ANAVEX®2-73 also resulted in clinically meaningful improvements as measured by the global
composite score of Parkinson’s disease symptom severity, MDS-Unified Parkinson’s Disease Rating Scale (“MDS-UPDRS”)
total score on top of standard of care including dopaminergic therapy, levodopa and other anti-PD medications after 14 weeks of treatment,
suggesting ANAVEX®2-73’s potential capability of slowing and reversing symptoms that progress in Parkinson’s
disease. In addition, the trial confirmed the precision medicine approach of targeting SIGMAR1 as a genetic biomarker in response to
ANAVEX®2-73 may result in improved clinical outcomes.
A 48-week Open Label Extension
(“OLE”) ANAVEX2-73-PDD-EP-001 Phase 2 trial was offered to participants after completion of the double-blind placebo-controlled
ANAVEX2-73-PDD-001 Phase 2 trial discussed above. The OLE trial assessed safety, tolerability and efficacy, measuring among others, MDS-Unified
Parkinson’s Disease Rating Scale Parts I, II, III, REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ), Clinical Global
Impression - Improvement (CGI-I), as well as cognitive efficacy endpoint Montreal Cognitive Assessment (MoCA) over a 48-week period.
In March 2023, we reported
the preliminary ANAVEX2-73-PDD-EP-001 OLE trial data, which demonstrated longitudinal beneficial effects of ANAVEX®2-73
on the pre-specified primary and secondary objectives. Preliminary analysis reveals that ANAVEX®2-73 was found to be generally
safe and well tolerated; and safety findings in this trial were consistent with the known safety profile of ANAVEX®2-73.
In respect to efficacy, across all efficacy endpoints, patients performed better while on ANAVEX®2-73. While all patients
were on drug holiday due to COVID-19 between the DB EOT and the OLE Baseline, the respective efficacy endpoints, including the MDS-UPDRS
Part II + III and CGI-I, measured at the end of trial of the double-blind study (DB EOT) and the OLE Baseline, were worsening, as expected
in a progressive disease like Parkinson’s. However, when patients resumed daily oral ANAVEX®2-73 treatment, a consistent
improvement was observed during the extension phase from OLE Baseline through each of OLE Week 24 and OLE Week 48. These results are
consistent with the pattern observed for all efficacy measures in the extension phase. The two endpoints, MDS-UPDRS Part II + III and
CGI-I measured in this study are the planned primary and key secondary endpoints in our forthcoming pivotal 6-month Parkinson’s
disease study.
In January 2021, we were awarded
a research grant of $1.0 million from The Michael J. Fox Foundation for Parkinson’s Research to develop ANAVEX®2-73
for the treatment of Parkinson’s disease. The award will explore utilization of PET imaging biomarkers to enable measurement of
target engagement and pathway activation of the SIGMAR1 with clinically relevant doses including in people with Parkinson’s disease.
Schizophrenia, Frontotemporal
Dementia and Alzheimer’s disease
In July 2020, we commenced
the First-in-Human Phase 1 clinical trial of ANAVEX®3-71. ANAVEX®3-71 was previously granted orphan drug
designation for the treatment of Frontotemporal Dementia (“FTD”) by the FDA. ANAVEX®3-71 is an orally
administered small molecule targeting sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases.
In preclinical studies, ANAVEX®3-71 demonstrated disease-modifying activity against the major hallmarks of Alzheimer’s
disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, as well as beneficial effects on mitochondrial
dysfunction and neuroinflammation.
The Phase 1 clinical trial
was a prospective double-blind, randomized, placebo-controlled trial in Australia. A total of 36 healthy male and female subjects were
included. Single escalating doses of ANAVEX®3-71 were administered in order to evaluate the safety, tolerability, and
PK of ANAVEX®3-71 and the effects of food and gender on its PK in healthy volunteers.
The trial met its primary
and secondary endpoints of safety, with no serious adverse events (“SAEs”) or dose-limiting toxicities observed. ANAVEX®3-71
was well tolerated in all cohorts receiving ANAVEX®3-71 in single doses ranging from 5 mg to 200 mg daily with no SAEs
and no significant lab abnormalities in any subject. In the trial, ANAVEX®3-71 exhibited linear PK. Its pharmacokinetics
was also dose proportional for doses up to 160 mg. Gender had no effect on the PK of the drug and food had no effect on the bioavailability
of ANAVEX®3-71. The trial also met the secondary objective of characterizing the effect of ANAVEX®3-71
on electrocardiogram (“ECG”) parameters. There were no clinically significant ECG parameters throughout the trial.
Participant QTcF measures were normal across all dose groups with no difference between ANAVEX®3-71 and placebo.
In October 2023 a peer-reviewed
publication in the journal Neurobiology of Aging, titled “Early treatment with an M1 and sigma-1 receptor agonist prevents cognitive
decline in a transgenic rat model displaying Alzheimer’s-like amyloid pathology”, featured the orally available small molecule
ANAVEX®3-71 (AF710B). The preclinical study described the potential disease-modifying properties of ANAVEX®3-71
on Alzheimer’s disease pathology as a possible drug candidate for a potential once daily oral preventive strategy for Alzheimer’s
disease.
In January 2024, in another
peer-reviewed publication in the journal Clinical Pharmacology in Drug Development, entitled, ‘Population-Based Characterization
of the Pharmacokinetics and Food Effect of ANAVEX3-71, a Novel Sigma-1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development
for Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer’s Disease’, reported the Population-based characterization
of the PK and food effect of ANAVEX®3-71 as part of the single ascending dose study in healthy participants with the primary
objective of assessing dose proportionality of ANAVEX®3-71, and to characterize the effect of food on the PK of ANAVEX®3-71.
The results from this PK evaluation demonstrated that ANAVEX®3-71, at single ascending doses of 5 to 200 mg, is linear,
dose proportional, and time invariant. Food had no effect on the PK of ANAVEX®3-71. This data also expands the safety
objectives met in this first-in-human study of ANAVEX®3-71, further supporting its drug development program.
Based on these results, and
ANAVEX®3-71’s pre-clinical profile, we intend to advance ANAVEX®3-71 into a biomarker-driven clinical
development dementia program for the treatment of schizophrenia, FTD and Alzheimer’s disease, evaluating longitudinal effect of
treatment with ANAVEX®3-71.
Schizophrenia
In March 2024, we commenced
the U.S. FDA cleared ANAVEX®3-71-SZ-001 clinical trial, a double-blind, placebo-controlled Phase 2 trial in schizophrenia.
The trial consists of two parts to explore multiple ascending doses in individuals with schizophrenia followed by a 28-day treatment
period in a larger cohort. The trial will utilize standard clinical outcome measures for schizophrenia including the Positive and Negative
Symptoms Scale (PANSS), and novel fluid and electrophysiological biomarkers will also be assessed, leveraging several advances in electroencephalography/event-related
potential (EEG/ERP) biomarkers in schizophrenia developed in collaboration with the industry-led ERP Biomarker Qualification Consortium.
In addition to the electrophysiological biomarkers, we are also applying novel neuroinflammatory, metabolomic, and transcriptomic biomarkers
at the intersection of schizophrenia pathophysiology and ANAVEX®3-71’s novel, dual mechanism of action.
Recent Developments
In May 2024, we announced
the addition and appointment of new senior team members including the appointment of Juan Carlos Lopez-Talavera, MD, PhD as Senior Vice
President, Head of Research and Development, Terrie Kellmeyer, PhD as Senior Vice President of Clinical Development, and Jeffrey Edwards,
PhD as Vice President of Clinical Pharmacology and Science. Each of these team members bring valuable industry experience with a track
record of successfully bringing drugs to market.
Corporate Information
Our principal executive office
is located at 630 5th Avenue, 20th Floor, New York, NY 10111-0100, and our telephone number is (844) 689-3939. Our website address is
www.anavex.com. Information contained in our website is not a part of, nor incorporated by reference into, this prospectus. Also, this
prospectus may include the names of various government agencies or the trade names of other companies. Unless specifically stated otherwise,
the use or display by us of such other parties’ names and trade names in this prospectus is not intended to and does not imply
a relationship with, or endorsement or sponsorship of us by, any of these other parties.
RISK FACTORS
An investment in our common
stock involves significant risks. You should carefully consider the risk factors contained in our filings with the SEC, as well as all
of the information contained in any prospectus supplement, free writing prospectus and amendments thereto, before you decide to invest
in our common stock. Our business, prospectus, financial condition and results of operations may be materially and adversely affected
as a result of any of such risks. The value of our common stock could decline as a result of any of these risks. You could lose all or
part of your investment in our common stock. Some of our statements in sections entitled “Risk Factors” are forward-looking
statements. You should also consider the risks, uncertainties and assumptions discussed under “Part I—Item 1A—Risk
Factors” of our most recent Annual Report on Form 10-K for the year ended September 30, 2023, which is incorporated herein by reference,
as may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future. The risks and uncertainties
we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem
immaterial may also affect our business, prospectus, financial condition and results of operations.
CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTS
This prospectus includes forward-looking
statements. All statements other than statements of historical facts contained in this prospectus, including statements regarding our
anticipated future clinical and regulatory milestone events, future financial position, business strategy and plans and objectives of
management for future operations, are forward-looking statements. The words “believe,” “may,” “estimate,”
“continue,” “anticipate,” “intend,” “expect” “should,” “forecast,”
“potential,” “predict”, “could,” “would,” “will,” “suggest,”
“plan” and similar expressions, as they relate to us, are intended to identify forward-looking statements. Such
forward-looking statements include, without limitation, statements regarding:
| ● | volatility
in our stock price and in the markets in general, and the potential for a positive return
on investment in our securities; |
| ● | our
ability to successfully conduct preclinical studies and clinical trials for our product candidates; |
| ● | our
ability to raise additional capital on favorable terms and the impact of such activities
on our stockholders and stock price; |
| ● | our
ability to generate any revenue or to continue as a going concern; |
| ● | our
ability to execute our research and development plan on time and on budget; |
| ● | our
products candidates’ ability to demonstrate efficacy or an acceptable safety profile; |
| ● | our
ability to obtain the support of qualified scientific collaborators; |
| ● | our
ability, whether alone or with commercial partners, to successfully commercialize any of
our product candidates that may be approved for sale; |
| ● | our
ability to identify and obtain additional product candidates; |
| ● | our
reliance on third parties in non-clinical studies and clinical trials; |
| ● | our
ability to defend against product liability claims; |
| ● | our
ability to safeguard against security breaches; |
| ● | our
ability to obtain and maintain sufficient intellectual property protection for our product
candidates; |
| ● | our
ability to comply with our intellectual property licensing agreements; |
| ● | our
ability to defend against claims of intellectual property infringement; |
| ● | our
ability to comply with the maintenance requirements of the government patent agencies; |
| ● | our
ability to protect our intellectual property rights throughout the world; |
| ● | the
anticipated start dates, durations and completion dates of our ongoing and future clinical
trials; |
| ● | the
anticipated designs of our future clinical trials; |
| ● | our
ability to attract and retain qualified employees; |
| ● | the
impact of Fast Track designation on receipt of actual FDA approval; |
| ● | our
anticipated future regulatory submissions and our ability to receive regulatory approvals
to develop and market our product candidates, including any orphan drug or Fast Track designations;
and |
| ● | our
anticipated future cash position and ability to obtain funding for our operations. |
We
have based these forward-looking statements largely on our current expectations and projections
about future events, including the responses we expect from regulatory authorities and financial trends that we believe may affect our
financial condition, results of operations, business strategy, preclinical studies and clinical trials, and financial needs. These forward-looking
statements are subject to a number of risks, uncertainties and assumptions including without limitation the risks described in “Risk
Factors” in Part I, Item 1A of our Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 27,
2023 and our subsequent Quarterly reports on Form 10-Q. These risks are not exhaustive. Moreover, we operate in a very competitive and
rapidly changing environment. New risk factors emerge from time to time and it is not possible for our management to predict all risk
factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may
cause actual results to differ materially from those contained in any forward-looking statements. You should not rely upon forward-looking
statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements
will be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Any
forward-looking statement made by us in this prospectus is based only on information currently available to us and speaks only as of
the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that
may be made from time to time, whether as a result of new information, future developments or otherwise.
USE OF PROCEEDS
We will retain broad discretion
over the use of the net proceeds to us from the sale of our securities under this prospectus. Unless otherwise provided in the applicable
prospectus supplement, we currently expect to use the net proceeds that we receive from this offering for working capital and other general
corporate purposes. The expected use of net proceeds of this offering represents our current intentions based on our present plans and
business conditions. We cannot specify with certainty all of the particular uses for the net proceeds to be received upon the closing
of this offering.
PLAN OF DISTRIBUTION
We may sell the securities from time to time
pursuant to underwritten public offerings, “at-the-market” offerings, negotiated transactions, block trades or a combination
of these methods. We may sell the securities to or through one or more underwriters or dealers (acting as principal or agent), through
agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions:
| |
● |
at
a fixed price or prices, which may be changed; |
| |
|
|
| |
● |
at
market prices prevailing at the time of sale; |
| |
|
|
| |
● |
at
prices related to such prevailing market prices; or |
| |
|
|
| |
● |
at
negotiated prices. |
A prospectus supplement or supplements (and any
related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities,
including, to the extent applicable:
| |
● |
the name or names of the
underwriters, dealers or agents, if any; |
| |
|
|
| |
● |
the purchase price of the
securities or other consideration therefor, and the proceeds, if any, we will receive from the sale; |
| |
|
|
| |
● |
any over-allotment or other
options under which underwriters may purchase additional securities from us; |
| |
|
|
| |
● |
any agency fees or underwriting
discounts and other items constituting agents’ or underwriters’ compensation; |
| |
|
|
| |
● |
any public offering price; |
| |
|
|
| |
● |
any discounts or concessions
allowed or reallowed or paid to dealers; and |
| |
|
|
| |
● |
any securities exchange
or market on which the securities may be listed. |
Only underwriters named in the prospectus supplement
will be underwriters of the securities offered by the prospectus supplement. Dealers and agents participating in the distribution of
the securities may be deemed to be underwriters, and compensation received by them on resale of the securities may be deemed to be underwriting
discounts. If such dealers or agents were deemed to be underwriters, they may be subject to statutory liabilities under the Securities
Act.
If underwriters are used in the sale, they will
acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public
offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will
be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting
syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters
will be obligated to purchase all of the securities offered by the prospectus supplement, other than securities covered by any over-allotment
option. If a dealer is used in the sale of securities, we or an underwriter will sell the securities to the dealer, as principal. The
dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. To the extent
required, we will set forth in the prospectus supplement the name of the dealer and the terms of the transaction. Any public offering
price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time.
We may sell securities directly or through agents
we designate from time to time. We will name any agent involved in the offering and sale of securities and we will describe any commissions
payable to the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, the agent will act on a best-efforts
basis for the period of its appointment.
We may provide agents, underwriters and dealers
with indemnification against civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments
that the agents, underwriters or dealers may make with respect to these liabilities. Agents, underwriters and dealers, or their affiliates,
may engage in transactions with, or perform services for, us in the ordinary course of business.
All securities we may offer, other than common
stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but
will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of
the trading markets for any securities.
Any underwriter may engage in over-allotment,
stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Over-allotment
involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying
security so long as the stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other short-covering transactions
involve purchases of the securities, either through exercise of the over-allotment option or in the open market after the distribution
is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities
originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause
the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities
at any time.
Any underwriters that are qualified market makers
on the Nasdaq Capital Market may engage in passive market making transactions in the common stock on the Nasdaq Capital Market in accordance
with Regulation M under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement of offers
or sales of the common stock. Passive market makers must comply with applicable volume and price limitations and must be identified as
passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid
for such security; if all independent bids are lowered below the passive market maker’s bid, however, the passive market maker’s
bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities
at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.
DESCRIPTION OF CAPITAL
STOCK
Common Stock
We are authorized to issue 200,000,000 shares of common
stock with a par value of $0.001. As of July 22, 2024, we had 84,795,517 shares of common stock outstanding. Upon liquidation, dissolution
or winding up of the corporation, the holders of common stock are entitled to share ratably in all net assets available for distribution
to stockholders after payment to creditors. The common stock is not convertible or redeemable and has no preemptive, subscription or conversion
rights. There are no conversion, redemption, sinking fund or similar provisions regarding the common stock. Each outstanding share of
common stock is entitled to one vote on all matters submitted to a vote of stockholders. There are no cumulative voting rights.
Each stockholder is entitled to receive the dividends
as may be declared by our board of directors out of funds legally available for dividends and, in the event of liquidation, to share
pro rata in any distribution of our assets after payment of liabilities. Our board of directors is not obligated to declare a dividend.
Any future dividends will be subject to the discretion of our board of directors and will depend upon, among other things, future earnings,
the operating and financial condition of our Company, its capital requirements, general business conditions and other pertinent factors.
It is not anticipated that dividends will be paid in the foreseeable future.
Nevada Anti-Takeover Law and Charter and Bylaws Provisions
Nevada Revised Statutes sections 78.378 to 78.3793
provide state regulation over the acquisition of a controlling interest in certain Nevada corporations unless the articles of incorporation
or bylaws of the corporation provide that the provisions of these sections do not apply. The statute creates a number of restrictions
on the ability of a person or entity to acquire control of a Nevada company by setting down certain rules of conduct and voting restrictions
in any acquisition attempt, among other things. Our bylaws provide that these sections do not apply.
There are no provisions in our articles of incorporation
or our bylaws that would delay, defer or prevent a change in control of our Company.
Indemnification Of Directors And Executive Officers And Limitation
On Liability.
Our Bylaws provide that any person who was or
is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal,
administrative or investigative, by reason of the fact that such person is or was a director, officer, employee or agent of the Company
(or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise) shall be indemnified and held harmless by the Company to the fullest extent permitted by Nevada law
against expenses including attorneys’ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by
such person in connection with such proceeding.
The Bylaws also provide that the expenses of
officers and directors incurred in defending a civil or criminal action, suit or proceeding must be paid by the Company as they are incurred
and in advance of the final disposition of the action, suit or proceeding upon receipt of an undertaking by or on behalf of the director
or officer to repay the amount if it is ultimately determined by a court of competent jurisdiction that he is not entitled to be indemnified
by the Company. Such right of indemnification shall be a contract right which may be enforced in any manner desired by such person. Such
right of indemnification shall not be exclusive of any other right which such directors, officers or representatives may have or hereafter
acquire and, without limiting the generality of such statement, they shall be entitled to their respective rights of indemnification
under any bylaw, agreement, vote of stockholders, provision of law or otherwise, as well as their rights under the Bylaws.
The Bylaws provide that the Board of Directors
may cause the Company to purchase and maintain insurance on behalf of any person who is or was a director or officer of the Company,
or is or was serving at the request of the Company as a director or officer of another Company, or as its representative in a partnership,
joint venture, trust or other enterprise against any liability asserted against such person and incurred in any such capacity or arising
out of such status, whether or not the Company would have the power to indemnify such person.
Nevada Revised Statutes 78.751 and 78.7502 have
provisions that provide for discretionary and mandatory indemnification of officers, directors, employees, and agents of a corporation.
Under these provisions, such persons may be indemnified by a corporation against expenses, including attorney’s fees, judgment,
fines and amounts paid in settlement, actually and reasonably incurred by him in connection with the action, suit or proceeding, if he
acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation and
with respect to any criminal action or proceeding had no reasonable cause to believe his conduct was unlawful.
To the extent that a director, officer, employee
or agent has been successful on the merits or otherwise in defense of any action, suit or proceeding, or in defense of any claim, issue
or matter, the Nevada Revised Statues provide that he must be indemnified by the Company against expenses, including attorney’s
fees, actually and reasonably incurred by him in connection with the defense.
Section 78.7502 of the Nevada Revised Statues
also provides that any discretionary indemnification, unless ordered by a court or advanced by the Company, may be made only as authorized
in the specific case upon a determination that indemnification of the director, officer, employee or agent is proper in the circumstances.
The determination must be made:
| |
● |
By the stockholders; |
| |
|
|
| |
● |
By the Company’s Board of Directors by majority
vote of a quorum consisting of directors who were not parties to that act, suit or proceeding; |
| |
|
|
| |
● |
If a majority vote of a quorum consisting of directors
who were not parties to the act, suit or proceeding cannot be obtained, by independent legal counsel in a written opinion; or |
| |
|
|
| |
● |
If a quorum consisting of directors who were not parties
to the act, suit or proceeding cannot be obtained, by independent legal counsel in a written opinion. |
Transfer Agent and Registrar
The transfer agent and registrar
for our common stock is Nevada Agency and Transfer Company. The transfer agent and registrar’s address is 50 West Liberty Street,
Suite 880, Reno, NV 89501.
Listing on the Nasdaq Capital Market
Our common stock is listed
on the Nasdaq Capital Market under the symbol “AVXL”.
LEGAL MATTERS
Unless otherwise specified
in the applicable prospectus supplement, the validity of the securities offered hereby will be passed upon for us by Snell & Wilmer,
L.L.P., Reno, Nevada. If legal matters in connection with offerings made by this prospectus are passed on by counsel for the underwriters,
dealers or agents, if any, that counsel will be named in the applicable prospectus supplement.
EXPERTS
The audited financial statements
incorporated by reference in this prospectus and elsewhere in the registration statement have been so incorporated by reference in reliance
upon the reports of Grant Thornton LLP, independent registered public accountants, upon the authority of said firm as experts in accounting
and auditing.
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and other reports and
other information with the SEC under the Exchange Act. Our filings with the SEC are also available to the public from commercial document
retrieval services and at the SEC’s website at www.sec.gov.
We make available free of charge on our internet
website at www.anavex.com our annual reports on Form 10-K, our quarterly reports on Form 10-Q, our current reports on Form 8-K and any
amendments to those reports, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the
SEC. Information contained on our website is not incorporated by reference into this prospectus and you should not consider such information
as part of this prospectus.
DOCUMENTS INCORPORATED
BY REFERENCE
The SEC allows us to “incorporate
by reference” into this prospectus certain information that we file with the SEC, which means that we can disclose important information
to you by referring you to other documents separately filed by us with the SEC that contain such information. The information we incorporate
by reference is considered to be part of this prospectus and information we later file with the SEC will automatically update and supersede
the information in this prospectus. The following documents filed by us with the SEC pursuant to Section 13(a) of the Exchange Act and
any of our future filings under Sections 13(a), 13(c), 14 or 15 (d) of the Exchange Act, except for information furnished under Item
2.02 or 7.01 of Current Report on Form 8-K, or exhibits related thereto, made before the termination of the offering are incorporated
by reference herein:
| ● | our
Annual Report on Form
10-K for the fiscal year ended September 30, 2023, filed with the SEC on November 27,
2023; |
| ● | our
Quarterly Report on Form
10-Q for the quarter ended December 31, 2023 that we filed with the SEC on February 7,
2024 and our Quarterly Report on Form
10-Q for the quarter ended March 31, 2024 that we filed with the SEC on May 9, 2024; |
| ● | our
Current Report on Form
8-K filed with the SEC on June 21, 2024, to the extent information therein is filed and
not furnished; and |
| ● | the
description of our common stock contained in the registration statement on Form
8-A, filed with the SEC on October 23, 2015, as updated by Exhibit
4.1 to our Annual Report on Form 10-K for the fiscal year ended September 30, 2022, filed
with the SEC on November 28, 2022, together with any amendment or report filed for the purpose
of updating such description. |
You should rely only on the
information incorporated by reference or provided in this prospectus. We have authorized no one to provide you with different information.
You should not assume that the information in this prospectus is accurate as of any date other than the date on the front of this document.
In addition, all documents subsequently filed by us pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act (other than any
such documents or portions thereof that are furnished under Item 2.02 or Item 7.01 of Form 8-K, unless otherwise indicated therein, including
any exhibits included with such Items) before the date the offering of securities hereunder is terminated or complete are deemed to be
incorporated by reference into, and to be a part of, this prospectus.
We will provide to each person,
including any beneficial owner, to whom a prospectus is delivered, a copy of any or all of the reports or documents that have been incorporated
by reference in the prospectus contained in the registration statement but not delivered with the prospectus, other than an exhibit to
these filings unless we have specifically incorporated that exhibit by reference into the filing, upon written or oral request and at
no cost to the requester. Requests should be made by writing or telephoning us at the following address:
Anavex Life Sciences Corp.
630 5th Avenue, 20th Floor
New York, NY 10111-0100
(844) 689-3939
Anavex Life Sciences Corp.
Up to $150,000,000 of
Common Stock
PROSPECTUS
__________, 2024
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution.
The following table sets forth
the various expenses (other than underwriting discounts and commissions) in connection with the issuance and distribution of the securities
registered hereby. The Company will bear all of these expenses. All amounts are estimated except for the SEC registration fee:
| SEC registration fee |
|
$ |
22,140 |
|
| Legal fees and expenses |
|
|
50,000 |
|
| Accounting fees and expenses |
|
|
30,000 |
|
| Miscellaneous fees and expenses |
|
$ |
2,500 |
|
| Total expenses |
|
$ |
104,640 |
|
Item 15. Indemnification of Directors and Officers.
Under the Nevada Revised Statutes
(“NRS”), director immunity from liability to a company or its shareholders for monetary liabilities applies automatically
unless it is specifically limited by a company’s Articles of Incorporation.
Section 78.7502 of the NRS
allows, and the Company wishes to adopt, discretionary indemnification of its directors, officers, employees, and agents as provided
below.
Subsection (1) of Section
78.7502 of the NRS empowers a corporation to indemnify any person who was or is a party or is threatened to be made a party of any threatened,
pending, or completed action, suit, or proceeding, whether civil, criminal, administrative, or investigative (other than an action by
or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation,
or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership,
joint venture, trust or other enterprise, or as a manager of a limited-liability company, against expenses (including attorneys’
fees), judgments, fines, and amounts paid in settlement actually and reasonably incurred by him or her in connection with the action,
suit, or proceeding if the person (a) is not in breach of their fiduciary duty which breach involved intentional misconduct, fraud or
a knowing violation of law, or (b) acted in good faith and in a manner in which he or she reasonably believed to be in, or not opposed
to, the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe
the conduct was unlawful.
Subsection (2) of Section
78.7502 of the NRS empowers a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened,
pending, or completed action or suit by or in the right of the corporation to procure a judgment in favor by reason of the fact that
such person acted in any of the capacities set forth in subsection (1) enumerated above, against expenses, including amounts paid in
settlement and attorneys’ fees actually and reasonably incurred by the person in connection with the defense or settlement of such
action or suit if the person (a) was not in breach of their fiduciary duty, which breach involved intentional misconduct, fraud or a
knowing violation of law, or (b) acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best
interests of the corporation except that no indemnification may be made for any claim, issue, or matter as to which such person shall
have been adjudged by a court of competent jurisdiction, after exhaustion of any appeals taken therefrom, to be liable to the corporation
or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought
or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is
fairly and reasonably entitled to indemnity for such expenses as the court deems proper.
Subsection (3) of Section
78.7502 of the NRS provides that, unless a court orders indemnification or amounts are advanced pursuant to NRS 78.751(2) or any discretionary
indemnification under Subsections (1) or (2) of NRS 75.7502 must be authorized by a determination that such indemnification is proper.
This determination must be made by the stockholders, the majority vote of a quorum of the board of the directors not parties to the action,
suit or proceeding, or a written opinion by independent legal counsel ordered by a majority of the directors who were not parties to
the action, suit, or proceeding, or a quorum of directors who were not parties to the action, suit or proceeding cannot be obtained.
Subsection (1) of Section
78.751 of the NRS provides for mandatory indemnification of any person who is a director, officer, employee or agent to the extent that
the person is successful on the merits or otherwise in defense of (i) any threatened, pending or completed action, suit or proceeding,
whether civil, criminal, administrative or investigative, including, without limitation, an action by or in the right of the corporation,
by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the
request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other
enterprise; or (ii) any claim, issue or matter therein, against expenses actually and reasonably incurred by the person in connection
with defending the action, including, without limitation, attorney’s fees.
Additionally, NRS 78.138(7)
provides, with limited statutory exceptions relating to a director’s duty when confronted with a change or potential change in
control of the corporation, or unless the articles of incorporation or an amendment thereto (in each case filed on or after October 1,
2003) provide for greater individual liability, that a director or officer is not individually liable to a corporation or its stockholders
or creditors for any damages as a result of any act or failure to act in his or her capacity as a director or officer unless it is proven
that: (i) the presumption that a director has acted in good faith, on an informed basis and with a view to the interest of the corporation
has been overcome; (ii) the act or failure to act constituted a breach of his or her fiduciary duties as a director or officer; and (ii)
the breach of those duties involved intentional misconduct, fraud or a knowing violation of law.
Our Bylaws provide that any
person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding,
whether civil, criminal, administrative or investigative, by reason of the fact that such person is or was a director, officer, employee
or agent of the Company (or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise) shall be indemnified and held harmless by the Company to the fullest extent permitted
by Nevada law against all expenses, liability and loss (including attorneys’ fees, judgments, fines and amounts paid or to be paid
in settlement) reasonably incurred by such person in connection. The expenses of officers and directors incurred in defending a civil
or criminal action, suit or proceeding must be paid by the Company as they are incurred and in advance of the final disposition of the
action, suit or proceeding upon receipt of an undertaking by or on behalf of the director or officer to repay the amount if it is ultimately
determined by a court of competent jurisdiction that he is not entitled to be indemnified by the Company. Insofar as indemnification
for liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors, officers, and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
In the event that a claim
for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer,
or controlling person in the successful defense of any action, suit, or proceeding) is asserted by such director, officer, or controlling
person connected with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as
expressed in the Securities Act and will be governed by the final adjudication of such issue.
The articles and bylaws provide
that we will indemnify our directors and officers and may indemnify its employees or agents to the fullest extent permitted by law against
liabilities and expenses incurred in connection with litigation in which they may be involved because of their offices with us. However,
nothing in our articles of incorporation or bylaws protects or indemnifies a director, officer, employee or agent against any liability
to which he would otherwise be subject by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties
involved in the conduct of his office. To the extent that a director has been successful in defense of any proceeding, the Nevada Revised
Statutes provide that he shall be indemnified against reasonable expenses incurred in connection therewith.
Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant
to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public
policy and is, therefore, unenforceable.
Item 16. Exhibits.
† Filed herewith.
* To be filed by amendment or as an exhibit to a document to be incorporated
by reference herein in connection with an offering of the offered securities.
Item 17. Undertakings.
The undersigned registrant hereby undertakes:
(a) (1) To file,
during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
| |
(i) |
to include any prospectus required by Section
10(a)(3) of the Securities Act of 1933, as amended; |
| |
(ii) |
to reflect in the prospectus any facts or events arising after the
effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the
aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing,
any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which
was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of
prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than
20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” exhibit
attached to the effective registration statement; and |
| |
|
|
| |
(iii) |
to include any material information with respect to the plan of distribution
not previously disclosed in the registration statement or any material change to such information in the registration statement; |
Provided, however, Paragraphs
(a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment
by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section
15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form
of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.
| |
(2) |
That, for the purpose of determining any
liability under the Securities Act of 1933, as amended, each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof. |
| |
(3) |
To remove from registration by means of a
post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. |
| |
(4) |
That, for the purpose of determining liability
under the Securities Act of 1933, as amended, to any purchaser: |
| |
(i) |
Each prospectus filed by the registrant pursuant
to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of
and included in the registration statement; and
|
| |
(ii) |
Each prospectus required to be filed pursuant
to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant
to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act
of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus
is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus.
As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall
be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which
the prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration
statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that
is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede
or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or
made in any such document immediately prior to such effective date. |
| |
(5) |
That, for the purpose of determining liability
of the registrant under the Securities Act of 1933, as amended, to any purchaser in the initial distribution of the securities, the
undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration
statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold
to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and
will be considered to offer or sell such securities to such purchaser: |
| |
(i) |
Any preliminary prospectus or prospectus
of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; |
| |
(ii) |
Any free writing prospectus relating to the offering prepared by or
on behalf of the undersigned registrant or used or referred to by the undersigned registrant; |
| |
|
|
| |
(iii) |
The portion of any other free writing prospectus
relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf
of the undersigned registrant; and |
| |
(iv) |
Any other communication that is an offer
in the offering made by the undersigned registrant to the purchaser. |
| |
(b) |
That, for purposes of determining any liability
under the Securities Act of 1933, as amended, each filing of the registrant’s annual report pursuant to Section 13(a) or Section
15(d) of the Securities Exchange Act of 1934, as amended, (and, where applicable, each filing of an employee benefit plan’s
annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934, as amended) that is incorporated by reference in
the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
| |
(c) |
Insofar as indemnification for liabilities arising under the Securities
Act of 1933, as amended, may be permitted to directors, officers and controlling persons of the registrant pursuant to the provisions
described in Item 15 above, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is
against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer
or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director,
officer or controlling person in connection with the securities being registered, that the registrant will, unless in the opinion
of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the Securities Act of 1933, as amended, and will be governed
by the final adjudication of such issue. |
SIGNATURES
Pursuant to the requirements
of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the city of New York, state of New York, on July 29, 2024.
| |
ANAVEX
LIFE SCIENCES CORP. |
| |
|
|
| |
By: |
/s/
Christopher Missling, PhD |
| |
Name: |
Christopher Missling, PhD |
| |
Title: |
Chief Executive Officer, Principal |
| |
|
Executive Officer and Director |
POWER OF ATTORNEY AND SIGNATURES
We, the undersigned officers
and directors of Anavex Life Sciences Corp., do hereby constitute and appoint Christopher Missling, PhD our true and lawful attorney-in-fact
and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to
sign any and all amendments to this Registration Statement, and to file the same, with exhibits thereto, and other documents in connection
therewith, with the SEC, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act
and thing requisite are necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do
in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do
or cause to be done by virtue hereof.
Pursuant to the requirements
of the Securities Act of 1933, this registration statement has been signed below by the following persons on behalf of the registrant
and in the capacities and on the dates indicated below:
| Signatures |
|
Title(s) |
|
Date |
| |
|
|
|
|
| /s/ Christopher
Missling, PhD |
|
|
|
July 29, 2024 |
| Christopher Missling, PhD |
|
Chief Executive Officer
(Principal Executive Officer) and Director |
|
|
| |
|
|
|
|
| /s/
Sandra Boenisch |
|
|
|
July
29, 2024 |
| Sandra Boenisch, CPA, CGA |
|
Principal Financial Officer
and Treasurer (Principal Accounting Officer) |
|
|
| |
|
|
|
|
| /s/
Jiong Ma, PhD |
|
|
|
July
29, 2024 |
| Jiong Ma, PhD |
|
Director, Chair |
|
|
| |
|
|
|
|
| /s/
Athanasios Skarpelos |
|
|
|
July 29,
2024 |
| Athanasios Skarpelos |
|
Director |
|
|
| |
|
|
|
|
| /s/
Claus van der Velden, PhD |
|
|
|
July
29, 2024 |
| Claus van der Velden, PhD |
|
Director |
|
|
| |
|
|
|
|
| /s/
Steffen Thomas, PhD |
|
|
|
July
29, 2024 |
| Steffen Thomas, PhD |
|
Director |
|
|
| |
|
|
|
|
| /s/
Peter Donhauser, D.O. |
|
|
|
July 29,
2024 |
| Peter Donhauser, D.O. |
|
Director |
|
|
22
EXHIBIT 5.1
July 29, 2024
Anavex Life Sciences Corp.
51 West 52nd Street, 7th Floor
New York, New York 10019-6163
Re: Form S-3
Ladies and Gentlemen:
We have acted as special counsel to Anavex Life Sciences Corp., a Nevada corporation
(the “Company”) in connection with the registration statement on Form S-3 and the related prospectus (the “Registration
Statement”) filed on the date of this letter by the Company, with the Securities and Exchange Commission (the “Commission”)
pursuant to the Securities Act of 1933, as amended (the “Securities Act”), relating to the registration of up to an aggregate
amount of $150,000,000 of the Company’s common stock, par value $0.001 per share (the “Shares”). Capitalized terms used
but not defined in this opinion letter have the meanings given to those terms in the Registration Statement.
This opinion is being furnished in connection with the requirements of Item
601(b)(5)(i) of Regulation S-K under the Securities Act, and no opinion is expressed in this letter as to any matter pertaining
to the contents of the Registration Statement, other than as expressly stated in this letter with respect to the issuance of the Shares.
You have requested our opinion as to the matters set forth below in connection
with the Registration Statement. For purposes of rendering this opinion, we have examined the Registration Statement, the Company’s
articles of incorporation, as amended, and bylaws, as amended, and the corporate action of the Company that provides for the issuance
of the Shares, and we have made such other investigation as we have deemed appropriate. We have examined and relied upon certificates
of public officials and, as to certain matters of fact that are material to our opinion, we have also relied on certificates made by officers
of the Company. In rendering our opinion, in addition to the assumptions that are customary in opinion letters of this kind, we have assumed
the genuineness of signatures on the documents we have examined, the conformity to authentic original documents of all documents submitted
to us as copies, that the Registration Statement has become effective and has been properly filed, and that the Company will have sufficient
authorized and unissued shares of common stock available with respect to any of the Shares issued after the date of this letter. We have
not verified any of these assumptions.
ALBUQUERQUE BOISE DALLAS DENVER LAS VEGAS LOS ANGELES LOS CABOS ORANGE COUNTY
PHOENIX PORTLAND RENO SALT LAKE CITY SAN DIEGO SEATTLE TUCSON WASHINGTON, D.C.
Anavex
Life Sciences Corp.
July
29, 2024
Page 2
This opinion is rendered as of the date of this letter and is limited to matters
of Nevada corporate law, including applicable provisions of the Nevada Constitution and reported judicial decisions interpreting those
laws. We express no opinion as to the laws of any other state, the federal law of the United States, or the effect of any applicable federal
or state securities laws.
Based upon and subject to the foregoing, it is our opinion that, when an issuance
of the Shares has been duly authorized by all necessary action of the Company, and, when such Shares have been issued and paid for as
described in the Registration Statement, the Shares will be validly issued, fully paid, and nonassessable.
We consent to the filing of this opinion as an exhibit to the Registration
Statement and to the reference to this firm under the caption “Legal Matters”. In giving our consent we do not admit that
we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations under such
act.
| |
Very truly yours, |
| |
/s/ Snell & Wilmer L.L.P. |
| |
Snell & Wilmer L.L.P. |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM
We have issued our reports dated November 27, 2023 with respect to the
consolidated financial statements and internal control over financial reporting of Anavex Life Sciences Corp. included in the Annual Report
on Form 10-K for the year ended September 30, 2023, which are incorporated by reference in this Registration Statement. We consent to
the incorporation by reference of the aforementioned reports in this Registration Statement, and to the use of our name as it appears
under the caption “Experts.”
/s/ GRANT
THORNTON LLP
Melville, New York
July 29, 2024
Exhibit 107
Calculation of Filing Fee Tables
Form S-3
(Form Type)
Anavex Life Sciences Corp.
(Exact Name of Registrant
as Specified in its Charter)
Table 1: Newly Registered
Securities
| |
Security
Type |
Security Class Title |
Fee Calculation
or Carry
Forward
Rule |
Amount
Registered |
Proposed
Maximum
Offering
Price Per
Unit |
Maximum
Aggregate
Offering
Price |
Fee
Rate |
Amount of
Registration
Fee |
Carry
Forward Form
Type |
Carry
Forward
File Number |
Carry
Forward Initial
Effective
Date |
Filing Fee
Previously
Paid In
Connection
with Unsold
Securities to
be Carried
Forward |
| Newly Registered Securities |
| Fees to Be Paid |
Equity |
Common Stock, $0.001 par value per share |
457(o) |
(1) |
(1) |
$150,000,000 |
$147.60per
$1,000,000 |
$22,140 (2) |
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Fees Previously Paid |
- |
- |
- |
- |
- |
- |
- |
- |
|
|
|
|
| Carry Forward Securities |
| Carry Forward Securities |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| |
Total Offering Amounts |
|
$150,000,000 |
- |
$22,140 (2) |
|
|
|
|
| |
Total Fees Previously Paid |
|
|
|
- |
|
|
|
|
| |
Total Fee Offsets |
|
|
|
- |
|
|
|
|
| |
Net Fee Due |
|
|
|
$22,140 |
|
|
|
|
| (1) |
Pursuant to Instruction 2.A(iii)(b) of Item 16(b) of Form S-3, this information is not required to be included. An indeterminate aggregate initial offering price or number of shares of Common Stock is being registered as may be issued at indeterminate prices from time to time with an aggregate initial offering price not to exceed $150,000,000. |
| (2) |
Calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended. |
Anavex Life Sciences (NASDAQ:AVXL)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Anavex Life Sciences (NASDAQ:AVXL)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
